Week of 20–27 October 2026 · HealthTech
This was a quiet HealthTech week: 13 rounds worth roughly $73M and one acquisition, compared with about $250M the week before. Almost every deal was seed or Series A. Two themes stood out. Medical AI keeps running into the same problem, getting good data, and the funded startups are solving it with linked hospital records, virtual patients and records patients control themselves. In India, the biggest rounds went to companies building physical clinic networks for people far from hospitals.
THE DIGEST
🇬🇧 adsilico raises a £10M Series A to test medical devices on virtual patients
PXN Ventures led the round, with existing investors Northern Gritstone and Parkwalk. The University of Leeds spin-out runs “in-silico” trials: it uses AI to create large populations of simulated patients, then tests how a medical device such as a heart valve performs on them before any human trial. This can cut development costs, reduce animal testing, and partly replace expensive human trials. The round follows a £3.5M seed in 2024.
🇮🇳 CureBay raises about ₹100 crore (about $10.5M) for rural healthcare
IvyCap Ventures led ₹69 crore of equity, alongside more than ₹30 crore of debt from Trifecta Capital, Alteria Capital and VentureSoul Partners. CureBay runs more than 250 tech-equipped clinics across seven Indian states, supported by a network of over 1,800 community health workers. It has served more than 1.7 million patients and runs more than 400 health camps a month. It ended its last financial year with about ₹170 crore in annual recurring revenue, plans to double that this year, and will expand into Andhra Pradesh.
🇮🇳 Clinics On Cloud raises a reported ₹120 crore Series A
The money reportedly came from Dubai-based investors at a ₹600 crore valuation, to build “microclinics” around the world. The company is known for its Health ATMs: kiosks that check more than 60 health measures in under 10 minutes. It has more than 2,500 of them installed across India.
🇺🇸 BioStack raises a $9.5M seed to turn hospital records into AI training data
Investors include Peak XV, Afore Capital, DCVC, Emerson Collective and Y Combinator. BioStack links scattered clinical records (doctors’ notes, lab results, imaging, medications and outcomes) into one history per patient, with identifying details removed, so AI companies can train models on how diseases progress and treatments work. Its network covers more than 100 million such records across the US, India, Brazil and Argentina.
🇸🇬 Genie Health raises a $3M seed
The Nadathur Family Office led the round, with Liminal, a founder studio backed by Temasek. CEO Hari V. Krishnan previously ran PropertyGuru and led its $1.1B sale to EQT. Genie’s consumer app gathers a person’s lab results, health reports and wearable data in one place and explains what they mean. A second product uses AI to handle clinics’ patient bookings and follow-ups.
Also raising this week:
- 🇺🇸 Kivo Health: $10M Series A for virtual rehab for chronic lung disease
- 🇺🇸 Parasol Medtech: $2.75M pre-seed for a stroke-prevention device that seals off part of the heart with a gel instead of a permanent implant. It was founded by University of Chicago cardiologist Atman Shah.
- 🇰🇷 MyBenefit: $2.27M Series A with body-composition device maker InBody as a strategic investor
- 🇺🇸 Vinyl Health: $2M seed to give patients control of their own medical records
- 🇬🇧 Emerald: €1.66M, half from an Innovate UK grant and half from VCs including Sequel and Highgoal, for preventive healthcare
- 🇦🇪 Vitalls: $1.5M seed from EST Growmore
- 🇮🇹 DataAIMed: €1.2M led by Italian software group Maggioli
- 🇹🇿 Medikea: $1.2M to expand healthcare access in Tanzania
- 🇮🇳 Amaha: reportedly in talks to raise ₹100 crore for mental healthcare
EXITS & M&A
🇮🇳🇨🇦 Mapmygenome completes its purchase of dnaPower
The Hyderabad genomics company bought Vancouver-based dnaPower, which has sold DNA-based health, nutrition and longevity tests since 2008. It’s Mapmygenome’s second Canadian acquisition, after microbiome lab Microbiome Insights in 2025. Together they give it lab capacity and customers across Canada and the US.
THE ANALYSIS
1. Medical AI’s biggest problem is data
BioStack links hospital records, adsilico creates simulated patients, Vinyl Health gives patients their records, and Genie pulls scattered health data into one place. As Peak XV’s Pushpak Kedia put it, BioStack could become a key data source for the next generation of medical AI. The models exist; reliable, well-organised clinical data is what’s scarce.
2. Testing devices on virtual patients is becoming practical
adsilico’s raise more than doubles its seed. Testing devices on simulated patients before real ones could shorten approval timelines and cut animal testing. If regulators accept simulation evidence more widely, it could change how medical devices are developed.
3. India is funding clinics, not just apps
CureBay, Clinics On Cloud and Amaha all combine physical locations with digital tools. CureBay’s founder put it plainly: rural India doesn’t need another app, it needs care that works from the doorstep to the specialist. Debt funding matters here too: almost a third of CureBay’s round was debt.
4. Prevention keeps attracting buyers and backers
Mapmygenome is buying its way into North America, while Emerald and Genie raised for preventive care. It’s also notable that an Indian company is acquiring in Canada, reversing the usual direction of cross-border healthtech deals.
5. Public money is backing European HealthTech
Northern Gritstone, an investor set up by three northern English universities, backed adsilico. Half of Emerald’s round was an Innovate UK grant, and Italian software group Maggioli led DataAIMed’s round. Europe’s HealthTech deals this week were small, and grants, university funds and strategic investors were behind most of them.
Bottom line: A small week, but a clear message: medical AI needs better data, and investors backed the companies that provide it, from linked hospital records to simulated patients. India’s biggest bets went to physical care networks, and the week’s one acquisition saw an Indian genomics company buy in Canada.
